GLENDA YBARRA: Open Payments
NPI 1063289056 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,797 in 116 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $710 · 2025 $2,797
Food & beverage: $2,797
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $641 |
| Vanda Pharmaceuticals Inc. | 10 | $326 |
| Otsuka America Pharmaceutical, Inc. | 10 | $323 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $300 |
| Axsome Therapeutics, Inc. | 9 | $265 |
| Corium, LLC | 9 | $217 |
| Alkermes, Inc. | 9 | $209 |
| Lundbeck LLC | 7 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $141 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Auvelity, Azstarys, HETLIOZ, FANAPT, ARISTADA.
Industry payments across FL — which companies pay providers there.
